The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.
The $649 NGS test screens for 193 disorders, can be ordered online, and is designed to supplement standard state newborn screening services.
Neurovascular Diagnostics intends to commercialize a test for unruptured intracranial aneurysm tests that use RNA expression signatures.
During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
The group now plans to run the 32-gene panel in clinical trials to demonstrate its utility and make the case for offering it within Canada's healthcare system.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.
The Sentosa SA201 HSV-1/2 PCR test detects herpes virus DNA from oral or anal skin lesions in symptomatic patients.
Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.
Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.
The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
Although a draft guidance last month recommended against use of molecular tests to guide chemotherapy, the group's finalized decision is subject to price negotiation and other adjustments.